Deng Xia, Li Yanyan, Gu Tian, Wu Xunan, Sun Ziyan, Li Haoxiang, Yang Ling, Yuan Guoyue
Department of Endocrinology, Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, Jiangsu, China.
Department of Endocrinology, Pudong Hospital, Shanghai Fudan University, Zhenjiang, Jiangsu, China.
Acta Diabetol. 2025 Jun;62(6):915-923. doi: 10.1007/s00592-024-02408-9. Epub 2024 Dec 11.
Ectodysplasin A (EDA) is a novel hepatokine that plays a role in multiple metabolic-related diseases. The aim of this study was to investigate the association between serum EDA levels and metabolic syndrome (MetS).
A total of 348 subjects, 258 patients with MetS and 90 healthy controls were enrolled. Serum EDA levels were measured using an enzyme-linked immunosorbent assay (ELISA). The correlation between EDA and various metabolic components was assessed.
The serum EDA levels of subjects with metabolic syndrome (MetS) were significantly higher than those without [323.78 (259.68-400.74) vs. 254.82 (182.68-347.88) pg/mL, P < 0.001]. The serum EDA level increases with the increase in metabolic score. The linear regression model revealed that age, blood pressure, fasting insulin (FIns), high-density lipoprotein cholesterol (HDL-C), and HOMA-IR were independent factors influencing EDA levels. Furthermore, in the logistic regression model, subjects in the highest tertile of EDA had a significantly higher risk of MetS, higher blood pressure, hyperglycemia, and lower HDL-C compared to those in the lowest tertile. This conclusion remained valid after adjusting for multiple confounding factors.
The research results for the first time found that the circulating EDA levels in patients with metabolic syndrome were significantly elevated and associated with hypertension, hyperglycemia, lower HDL-C, and insulin resistance risk, indicating that EDA may play a role in the occurrence of metabolic syndrome and may be a potential therapeutic target for metabolic syndrome.
外胚层发育不良蛋白A（EDA）是一种新型肝源性激素，在多种代谢相关疾病中发挥作用。本研究旨在探讨血清EDA水平与代谢综合征（MetS）之间的关联。
共纳入348名受试者，其中258例MetS患者和90名健康对照。采用酶联免疫吸附测定（ELISA）法检测血清EDA水平。评估EDA与各种代谢成分之间的相关性。
代谢综合征（MetS）患者的血清EDA水平显著高于无MetS者[323.78（259.68 - 400.74）对254.82（182.68 - 347.88）pg/mL，P < 0.001]。血清EDA水平随代谢评分的增加而升高。线性回归模型显示，年龄、血压、空腹胰岛素（FIns）、高密度脂蛋白胆固醇（HDL-C）和HOMA-IR是影响EDA水平的独立因素。此外，在逻辑回归模型中，与最低三分位数的受试者相比，EDA最高三分位数的受试者患MetS、高血压、高血糖的风险显著更高，HDL-C更低。在调整多个混杂因素后，这一结论仍然有效。
研究结果首次发现，代谢综合征患者的循环EDA水平显著升高，且与高血压、高血糖、低HDL-C和胰岛素抵抗风险相关，表明EDA可能在代谢综合征的发生中起作用，可能是代谢综合征的一个潜在治疗靶点。
